The fixed-dose combination of sofosbuvir + velpatasvir (sold as Epclusa) has activity against all major strains, or genotypes, of hepatitis C virus (HCV). The combination of these drugs has been evaluated for possible and potential interactions with other drugs.
Here are recommendations from Epclusa manufacturer Gilead Sciences:
In people coinfected with HIV and HCV, the following drugs can be used:
What is clear from the drug interaction studies with Epclusa is that the anti-HIV drug efavirenz (Sustiva, Stocrin and in Atripla) must not be used because it can reduce absorption of velpatasvir by about 50%.
No loss of efficacy with oral contraceptives containing norgestimate/thinly estradiol should occur.
Sofosbuvir-velpatasvir does not appear to have significant interactions with cyclosporine (Neoral, Sandimmune) or tacrolimus (Advagraf, Prograf).
Complete details about drug interactions between sofosbuvir-velpatasvir and other medicines will be released in the future by Gilead.
Mogalian E, McNally J, Shen G, et al. Drug-drug interaction profile of sofosbuvir-velpatasvir fixed-dose combination. The International Liver Congress, 13-17 April 2017, Barcelona, Spain. Abstract FRI-168.
|Sofosbuvir + Velpatasvir (Epclusa) + Ribavirin for Retreatment|
|Sofosbuvir + Velpatasvir (Epclusa) in HIV Coinfection|
|Sofosbuvir + Velpatasvir (Epclusa) -- Improvements in Quality of Life, Energy and Emotional and Mental Health|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|Free Your (and Carl's) Mind: An Open Letter to Anthony Fauci About HIV Prevention Research Priorities|
|Let's Advance the Conversation Among Black Women on HIV and PrEP|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|